Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
Study sponsor: Kiora Pharmaceuticals, Inc. · KPRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-11Estimated
Enrollment · participants28Estimated
Source updated2026-09-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.